Late-Stage Expansions Could Be at Risk Under Medicare Negotiations
-
Mar 13, 2025
As CMS undergoes its pricing negotiations on the second round of drugs under the Medicare Drug Price Negotiation Program, a recent report reveals that manufacturer concerns over the program’s potential threat to drug development may be warranted. Researchers at the IQVIA Institute for Human Data Science analyzed initial drug approvals and expansions that followed and found that due to some aspects of the program, clinical development after a drug’s initial approval may indeed be impacted, according to a new report, titled Proliferation of Innovation Over Time: Frequency, Timing and Clinical Value of Expansions Post-Initial Approval.
Genentech USA, Inc., a member of the Roche Group, provided funding for the report.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.